Uudet riskin ennustamislähestymistavat sydän- ja verisuonisairauksien ensisijaiseen ehkäisyyn Italiassa: CVRISK-IT-tutkimus (CVRISK-IT) (CVRISK-IT)
Uudet riskin ennustamislähestymistavat sydän- ja verisuonisairauksien ensisijaiseen ehkäisyyn Italiassa: CVRISK-IT-tutkimus
The CVRISK-IT study aims to evaluate the health benefit of measuring genetic and imaging risk information in men and women considered at 'low-to-moderate' or 'high' risk of developing cardiovascular diseases (CVD) in a randomized controlled trial in Italian primary care settings. Our primary objective is to answer a fundamental question in the prevention and prediction of CVD in Italy and globally: is there any benefit in including additional information (such as genetic and/or imaging data) in estimating risk, in conjunction with lifestyle advice and medical treatment for primary prevention of CVD?
As a key secondary objective of the CVRISK-IT study, the goal is to build a large bioresource with clinical information and biological samples to facilitate a new generation of discovery and translational research that will advance understanding of the genetic, molecular and behavioural determinants as well as mechanisms of multiple chronic diseases in the Italian population. By contributing to the Rete Cardiologica database and the BBDCARDIO biobank, the CVRISK-IT study will also serve as a cornerstone for future investigations into the development and testing of early diagnostic technologies and preventive (or 'personalised precision health') interventions for chronic diseases.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This multicenter, open randomized trial will investigate the effects of providing additional CVD risk information alongside personalised lifestyle advice and medical treatment in a primary prevention context across Italy. Healthy individuals aged 40 to 80 years, with no prior history of CVD or diabetes, will be recruited in two phases from the cohort of 17 participating IRCCS across Italy and affiliated enrolling centers. The population enrolled in this study consists of subjects who have never participated in other cardiovascular prevention studies of the Rete Cardiologica.
Phase 1 - Identification of the study population and development of the bioresource: various recruitment sources will be used, including institutions, primary care centres/services, government agencies, occupational health services, and volunteer organizations (e.g., blood donors). Participants will provide informed consent, a blood sample, and complete an electronic questionnaire. Approximately 30,000 individuals will be recruited and assessed using SCORE2/SCORE2-OP risk prediction models. Those identified as 'very high' risk will receive immediate medical treatment and will not proceed to phase 2.
Phase 2 - Randomization and novel risk prediction interventions: Participants identified as 'low-to-moderate' or 'high' CVD risk during phase 1 will be randomized, following a 2x2 factorial design into four groups within 1 week upon enrolment: a control group (no additional risk information), and three intervention groups (genetic, imaging-based and genetic + imaging-based risk information). The goal is to randomize around 12,000 participants in phase 2 (~3,000 per trial arm). All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The remaining 18,000 participants who won't proceed to phase 2 will still be involved in the study and contacted through a phone call follow-up with specialist at the 5◦ and 10◦ year.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Ancona, Italia
- Rekrytointi
- Irccs Inrca
-
Ottaa yhteyttä:
- Roberto Antonicelli, MD
- Puhelinnumero: +390718003450
- Sähköposti: r.antonicelli@inrca.it
-
Genova, Italia
- Ei vielä rekrytointia
- IRCCS San Martino
-
Ottaa yhteyttä:
- Pietro Ameri, MD
- Sähköposti: pietro.ameri@unige.it
-
Milan, Italia
- Rekrytointi
- IRCCS Ospedale San Raffaele
-
Ottaa yhteyttä:
- Paolo Camici, MD
- Puhelinnumero: 02 2643 8190/8191
- Sähköposti: cvriskit@hsr.it
-
Milan, Italia
- Rekrytointi
- IRCCS Auxologico Italiano
-
Ottaa yhteyttä:
- Gianfranco Parati, MD
- Puhelinnumero: 02-61911.1
- Sähköposti: gianfranco.parati@unimib.it
-
Milan, Italia
- Rekrytointi
- IRCCS Cardiologico Monzino
-
Ottaa yhteyttä:
- Damiano Baldassarre, MD
- Puhelinnumero: +39 02.58002369
- Sähköposti: damiano.baldassarre@cardiologicomonzino.it
-
Milan, Italia
- Ei vielä rekrytointia
- IRCCS Fondazione Cà Granda- Policlinico Milano
-
Ottaa yhteyttä:
- Stefano Carugo, MD
- Sähköposti: stefano.carugo@policlinico.mi.it
-
Milan, Italia
- Ei vielä rekrytointia
- IRCCS Istituto Clinico Humanitas
-
Ottaa yhteyttä:
- Giuseppe Ferrante, MD
- Sähköposti: giuseppe.ferrante@hunimed.eu
-
Milan, Italia
- Rekrytointi
- IRCCS Mario Negri
-
Ottaa yhteyttä:
- Maria Carla Roncaglioni, MD
- Puhelinnumero: 0239014-501
- Sähköposti: cvrisk-it_fase1@marionegri.it
-
Milan, Italia
- Rekrytointi
- IRCCS Multimedica
-
Ottaa yhteyttä:
- Francesco Bandera, MD
- Puhelinnumero: 02.242091
- Sähköposti: francesco.bandera@multimedica.it
-
Naples, Italia
- Ei vielä rekrytointia
- Irccs Synlab Sdn
-
Ottaa yhteyttä:
- Carlo Cavaliere, MD
- Sähköposti: carlo.cavaliere@synlab.it
-
Palermo, Italia
- Ei vielä rekrytointia
- Irccs Ismett
-
Ottaa yhteyttä:
- Manlio Cipriani, MD
- Sähköposti: mcipriani@ismett.edu
-
Pavia, Italia
- Ei vielä rekrytointia
- IRCCS Istituti Clinici Scientifici Maugeri
-
Ottaa yhteyttä:
- Maria Teresa La Rovere, MD
- Sähköposti: mariateresa.larovere@icsmaugeri.it
-
Pavia, Italia
- Ei vielä rekrytointia
- IRCCS Fondazione Policlinico San Matteo
-
Ottaa yhteyttä:
- Eloisa Arbustini, MD
- Sähköposti: e.arbustini@smatteo.pv.it
-
Pozzilli, Italia
- Ei vielä rekrytointia
- IRCCS Neuromed
-
Ottaa yhteyttä:
- Maria Benedetta Donati, MD
- Sähköposti: mariabenedetta.donati@neuromed.it
-
Rome, Italia
- Ei vielä rekrytointia
- IRCCS Fondazione Policlinico Gemelli
-
Ottaa yhteyttä:
- Giovanna Liuzzo, MD
- Sähköposti: giovanna.liuzzo@policlinicogemelli.it
-
Rome, Italia
- Ei vielä rekrytointia
- IRCCS San Raffaele Roma
-
Ottaa yhteyttä:
- Massimo Volpe, MD
- Sähköposti: massimo.volpe@sanraffaele.it
-
San Donato Milanese, Italia
- Rekrytointi
- IRCCS Policlinico San Donato
-
Ottaa yhteyttä:
- Chiara Barberio, PhD
- Puhelinnumero: 02-52774838
- Sähköposti: cvriskit@grupposandonato.it
-
Ottaa yhteyttä:
- Ambra Cerri, PhD
-
Päätutkija:
- Lorenzo Menicanti, MD
-
Alatutkija:
- Emanuele Diangelantonio, MD
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age: 40-80 years
- Apparently healthy individuals without previous medical history of CVD or diabetes (based on medical diagnosis)
- Participant recruitment arranged only at selected IRCCS (and associated Spokes) as part of the 'Rete Cardiologica'
- Participants must have signed the Informed Consent and Data Privacy Treatment forms
- Participants must have a personal e-mail address and internet connection
Exclusion Criteria:
- Age ≤40 or ≥80 years
- Individuals have previous medical history related to CVD (e.g., heart failure, congenital heart disorder, coronary heart disease) based on medical diagnosis
- Candidates have previously participated in clinical studies of 'Rete Cardiologica' (e.g., PREVITAL)
- Medical diagnosis of mental disorders
- Pregnancy based on self-reported information
- Previous history of type 1 or type 2 diabetes (based on medical diagnosis)
- Oncology patients (based on physician indication)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Tehtävätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Ei väliintuloa: Control
No additional cardiovascular risk information/recommendation is provided to the subject other than SCORE2/SCORE2-OP results of phase I. Thereby, the control group does not undergo neither imaging nor genetic analysis. |
|
|
Kokeellinen: Imaging
Subjects randomized in the imaging arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on imaging data analysis (i.e., carotid ultrasound or calcium score) |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
|
Kokeellinen: Polygenic Risk Score (PRS)
Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on polygenic risk score (PRS) analysis obtained from blood samples collected at the baseline visit |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
|
Kokeellinen: Imaging and Polygenic Risk Score (PRS)
Subjects randomized in this arm receive personalized recommendations on lifestyle and, if necessary, therapeutic intervention based on both imaging data (e.g., carotid ultrasound and/or calcium score) and genetic analysis (e.g., PRS). |
All individuals will receive tailored lifestyle advice along with medical treatment based on their newly estimated CVD risk. The control group will also receive lifestyle advice along with medical treatment based only on their CVD risk provided at the baseline visit during phase I. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in CVD risk using SCORE2/SCORE2-OP
Aikaikkuna: 12 months
|
The primary short-term outcome (i.e., 12 months after communication of the newly estimated CVD risk, following the randomisation step) is the change in CVD risk measured using SCORE2/SCORE2-OP risk prediction models. The CVD risk categories used to classify healthy people according to these scores are: 1) Low-to-moderate CVD risk: <50 years = <2.5 %; 50-69 years = <5%; ≥ 70 years = <7.5%. High CVD risk: <50 years = 2.5 to <7.5%; 50-69 years = 5 to <10%; ≥ 70 years 7.5 to <15%; Very high CVD risk: <50 years = ≥7.5%; 50-69 years = ≥10%; ≥ 70 years = ≥ 15%. |
12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in cardiovascular modifiable risk factors
Aikaikkuna: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as cholesterol levels (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) (mg/dl) |
12 months
|
|
Change in cardiovascular modifiable risk factors
Aikaikkuna: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as blood pressure which will be measured 3 times in a row, and its average calculated (mmHg) |
12 months
|
|
Change in cardiovascular modifiable risk factors
Aikaikkuna: 12 months
|
Secondary short-term outcomes will include changes in objectively measured risk factors, such as smoking habits (e.g., switch from "usual smoker" to "not smoking anymore" categories) |
12 months
|
|
Change in CVD prevention-drugs prescription
Aikaikkuna: 12 months
|
Secondary short-term outcomes will include changes in CVD prevention-drugs prescription with respect to the baseline visit |
12 months
|
|
Evaluation of participant's adherence to ESC recommendations
Aikaikkuna: 12 months
|
By means of validated questionnaires, the assessment of participants' adherence to the lifestyle and dietary guidelines of the European Society of Cardiology (ESC) will be performed. If and where applicable, drugs prescription adherence will be evaluated as well as psychological outcomes |
12 months
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
CVD events recording in long-term period
Aikaikkuna: 5-10 years
|
The long-term outcomes will include the registration of CVD events in all enrolled participants in the long-term period (e.g., non-fatal myocardial infarction, acute coronary syndrome, percutaneous transluminal coronary angioplasty (PTCA), Coronary artery bypass grafting (CABG), non-fatal stroke), CVD mortality, and total mortality |
5-10 years
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S; Atlas Writing Group, European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022 Feb 22;43(8):716-799. doi: 10.1093/eurheartj/ehab892.
- Di Angelantonio E, Piepoli M, Castelvecchio S, Barberio C, Chiarello C, Cerri A, Boveri S, Cardani R, Ambrogi F, Guelfi S, Baldassarre D, Colombo G, Amato M, Baetta R, Arbustini E, Liuzzo G, Kaptoge S, Severino A, Ferrante G, La Rovere MT, Parati G, Pengo MF, Latini R, Roncaglioni MC, Rigoni M, De Curtis A, Frati L, Ameri P, Camici PG, Volpe M, Menicanti L. Integrating genetic and imaging information to enhance cardiovascular risk stratification: rationale and design of the CVRISK-IT randomised controlled trial. Eur Heart J Qual Care Clin Outcomes. 2026 Mar 4:qcag032. doi: 10.1093/ehjqcco/qcag032. Online ahead of print.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- CVRISK-IT
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .